FDA WARNING_LETTER - Beepothecary LLC - October 06, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On October 23, 2020, the FDA and FTC issued a Warning Letter to BEEpothecary regarding unapproved and misbranded products related to COVID-19. The agencies reviewed the company's websites (www.beepothecary.us, www.beepothecary.square.site) and social media (Facebook, Instagram, Twitter) on July 22, 2020, and October 6, 2020.
The FDA observed that products like "Elderberry, Honey & Propolis Syrup," "BEEbread," and "BEEHive Delight" were offered for sale with claims to mitigate, prevent, treat, diagnose, or cure COVID-19. These products are deemed unapproved new drugs under section 505(a) of the FD&C Act (21 U.S.C. § 355(a)) and misbranded drugs under section 502 (21 U.S.C. § 352). The introduction of these products into interstate commerce is prohibited by sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)).
The letter cites the public health emergency and national emergency declarations for COVID-19 as context for urgent FDA action. BEEpothecary is required to immediately cease selling these unapproved products. The company
ID · e473be0e-5d44-49c6-b719-7073a6d0c255
Full citation text and observation details available on the Dashboard.